2219 related articles for article (PubMed ID: 8253520)
21. Collateral sensitivity to thaliblastine and/or hyperthermia exhibited by a rat ovarian tumor cell line selected for resistance to cisplatin.
Chen G; Zeller WJ; Todorov DK
Anticancer Res; 1993; 13(5A):1269-75. PubMed ID: 8239496
[TBL] [Abstract][Full Text] [Related]
22. Glutathione S‑transferase isozyme alpha 1 is predominantly involved in the cisplatin resistance of common types of solid cancer.
Zou M; Hu X; Xu B; Tong T; Jing Y; Xi L; Zhou W; Lu J; Wang X; Yang X; Liao F
Oncol Rep; 2019 Feb; 41(2):989-998. PubMed ID: 30431119
[TBL] [Abstract][Full Text] [Related]
23. Modulation of cisplatin cytotoxicity by sulphasalazine.
Awasthi S; Sharma R; Singhal SS; Herzog NK; Chaubey M; Awasthi YC
Br J Cancer; 1994 Aug; 70(2):190-4. PubMed ID: 7914420
[TBL] [Abstract][Full Text] [Related]
24. Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review).
Toma S; Ugolini D; Palumbo R
Int J Oncol; 1999 Aug; 15(2):321-37. PubMed ID: 10402244
[TBL] [Abstract][Full Text] [Related]
25. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.
Creagan ET; Suman VJ; Dalton RJ; Pitot HC; Long HJ; Veeder MH; Vukov AM; Rowland KM; Krook JE; Michalak JC
J Clin Oncol; 1999 Jun; 17(6):1884-90. PubMed ID: 10561229
[TBL] [Abstract][Full Text] [Related]
26. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
27. The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro.
Geisinger KR; Berens ME; Duckett Y; Morgan TM; Kute TE; Welander CE
Cancer; 1990 Mar; 65(5):1055-61. PubMed ID: 2137365
[TBL] [Abstract][Full Text] [Related]
28. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Sharp SY; Rowlands MG; Jarman M; Kelland LR
Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
[TBL] [Abstract][Full Text] [Related]
29. The role of tamoxifen in combination with cisplatin on oral squamous cell carcinoma cell lines.
Kim MJ; Lee JH; Kim YK; Myoung H; Yun PY
Cancer Lett; 2007 Jan; 245(1-2):284-92. PubMed ID: 16513256
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel and SN-38 overcome cisplatin resistance of ovarian cancer cell lines by down-regulating the influx and efflux system of cisplatin.
Komuro Y; Udagawa Y; Susumu N; Aoki D; Kubota T; Nozawa S
Jpn J Cancer Res; 2001 Nov; 92(11):1242-50. PubMed ID: 11714450
[TBL] [Abstract][Full Text] [Related]
31. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells.
Levasseur LM; Greco WR; Rustum YM; Slocum HK
Cancer Chemother Pharmacol; 1997; 40(6):495-505. PubMed ID: 9332464
[TBL] [Abstract][Full Text] [Related]
32. Effect of tamoxifen on the multidrug-resistant phenotype in human breast cancer cells: isobologram, drug accumulation, and M(r) 170,000 glycoprotein (gp170) binding studies.
Leonessa F; Jacobson M; Boyle B; Lippman J; McGarvey M; Clarke R
Cancer Res; 1994 Jan; 54(2):441-7. PubMed ID: 7903910
[TBL] [Abstract][Full Text] [Related]
33. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
34. Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.
Lenzi R; Frost P; Abbruzzese JL
Anticancer Res; 1994; 14(1A):247-51. PubMed ID: 7513143
[TBL] [Abstract][Full Text] [Related]
35. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
Shen W; Liang B; Yin J; Li X; Cheng J
Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
[TBL] [Abstract][Full Text] [Related]
36. [Hormone dependence of malignant ovarian tumors--an in vitro model].
Schieder K; Bieglmayer C; Kölbl H
Geburtshilfe Frauenheilkd; 1989 May; 49(5):437-41. PubMed ID: 2544477
[TBL] [Abstract][Full Text] [Related]
37. Synergistic antiproliferative activity of tamoxifen and cisplatin on primary ovarian tumours.
Scambia G; Ranelletti FO; Benedetti Panici P; Piantelli M; De Vincenzo R; Bonanno G; Ferrandina G; Isola G; Mancuso S
Eur J Cancer; 1992; 28A(11):1885-9. PubMed ID: 1389532
[TBL] [Abstract][Full Text] [Related]
38. BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin.
Manzotti C; Pratesi G; Menta E; Di Domenico R; Cavalletti E; Fiebig HH; Kelland LR; Farrell N; Polizzi D; Supino R; Pezzoni G; Zunino F
Clin Cancer Res; 2000 Jul; 6(7):2626-34. PubMed ID: 10914703
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
Untch M; Sevin BU; Perras JP; Angioli R; Untch A; Hightower RD; Koechli O; Averette HE
Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
[TBL] [Abstract][Full Text] [Related]
40. Comparative study on the induction of cytostasis and apoptosis by ICI 182,780 and tamoxifen in an estrogen receptor-negative ovarian cancer cell line.
Ercoli A; Scambia G; Fattorossi A; Raspaglio G; Battaglia A; Cicchillitti L; Malorni W; Rainaldi G; Benedetti Panici P; Mancuso S
Int J Cancer; 1998 Mar; 76(1):47-54. PubMed ID: 9533761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
